Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Petition Against Increlex Approval Not "Compelling" – Agency Review

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Insmed's contention that Tercica's orphan drug Increlex lacked an adequate safety database to justify approval was contradicted by the "very large" amount of data relative to the size of the target population, according to Office of Drug Evaluation II Director Robert Meyer, MD

You may also be interested in...

Tercica Increlex Hypoglycemia Risk Mitigated By Dose Timing, Titration – FDA

FDA concerns over Tercica’s Increlex hypoglycemic seizure risk led to strengthened labeling on the need for dosing at meal time but were insufficient to warrant rejection of the extreme short stature therapy, agency review documents show.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts